×

Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1

  • US 9,708,604 B2
  • Filed: 03/16/2010
  • Issued: 07/18/2017
  • Est. Priority Date: 03/17/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method of upregulating a function of and/or the expression of a Delta-like 1 homolog (DLK1) polynucleotide having SEQ ID NOS:

  • 1 or 2 in human patient cells or tissues in vivo or in vitro comprising;

    contacting said cells or tissues with at least one antisense oligonucleotide of 12 to 30 nucleotides in length that specifically targets a region of a natural antisense oligonucleotide of the Delta-like 1 homolog (DLK1) polynucleotide selected from SEQ ID NO;

    3;

    thereby upregulating a function of and/or the expression of the Delta-like 1 homolog (DLK1) polynucleotide in patient cells or tissues in vivo or in vitro.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×